

# Research Article

# Small angle X-ray scattering analysis of ligand-bound forms of tetrameric apolipoprotein-D

© Claudia S. Kielkopf<sup>1,2,3</sup>, Andrew E. Whitten<sup>4</sup>, Brett Garner<sup>1,2,3</sup> and © Simon H.J. Brown<sup>1,2,3</sup>

<sup>1</sup>Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW, Australia; <sup>2</sup>School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, Australia; <sup>3</sup>Molecular Horizons, University of Wollongong, Wollongong, NSW, Australia; <sup>4</sup>Australian Nuclear Science and Technology Organisation, Lucas Heights, NSW, Australia

Correspondence: Simon H.J. Brown (simonb@uow.edu.au)



Human apolipoprotein-D (apoD) is a glycosylated lipocalin that plays a protective role in Alzheimer's disease due to its antioxidant function. Native apoD from human body fluids forms oligomers, predominantly a stable tetramer. As a lipocalin, apoD binds and transports small hydrophobic molecules such as progesterone, palmitic acid and sphingomyelin. Oligomerisation is a common trait in the lipocalin family and is affected by ligand binding in other lipocalins. The crystal structure of monomeric apoD shows no major changes upon progesterone binding. Here, we used small-angle X-ray scattering (SAXS) to investigate the influence of ligand binding and oxidation on apoD oligomerisation and conformation. As a solution-based technique, SAXS is well suited to detect changes in oligomeric state and conformation in response to ligand binding. Our results show no change in oligomeric state of apoD and no major conformational changes or subunit rearrangements in response to binding of ligands or protein oxidation. This highlights the highly stable structure of the native apoD tetramer under various physiologically relevant experimental conditions.

## Introduction

Apolipoprotein-D (apoD) is a  $\sim$ 25 kDa glycoprotein belonging to the protein family of lipocalins [1,2], a family which is characterised by high structural homology and the ability to bind and transport small hydrophobic ligands [3]. ApoD adopts a typical lipocalin fold of a  $\beta$ -barrel ligand pocket and an adjacent  $\alpha$ -helix (Figure 1, PDB ID: 2HZQ). Two disulphide bonds connect the N- and C-terminal segments to the  $\beta$ -barrel while a fifth free cysteine forms an intermolecular disulphide bond to apoA-II in plasma [4]. The crystal structure of apoD shows that upon progesterone binding, three side chains change conformation (Figure 1) [1]. ApoD is furthermore consistently glycosylated at two amino acids, with the exact glyco-composition being heterogeneous [5]. ApoD has an antioxidant function and plays a protective role in Alzheimer's disease [6,7]. Using small angle X-ray scattering (SAXS) and other techniques, we have previously shown that the apo form of native human apoD isolated from breast cyst fluid (BCF) forms a tetrameric oligomer that is stable upon dilution [8]. Oligomerisation is common in the lipocalin family and has been shown in other lipocalins to be influenced by ligand binding, salt concentration and pH [3,9–11]. Specifically, ligand binding affects oligomerisation and vice versa in lipocalins [11,12]. Ligand binding of  $\beta$ -lactoglobulin leads to dimer dissociation [11], and ligand binding of crustacyanin, a pigmentation protein, is critically dependent on dimer formation [12].

Ligand binding may affect not only oligomerisation but also the 3D structure of apoD, even though substantial changes were not observed in the crystal structure of recombinant monomeric apoD upon progesterone binding [1]. Hydrogen-deuterium exchange coupled with mass spectrometry (HDX-MS) has recently shown reduced deuterium exchange in the apoD ligand binding pocket as well as in peripheral regions upon progesterone binding, suggesting a stabilisation of these areas induced by progesterone [13]. Given the reported difficulties in crystallising native apoD [14], X-ray crystallography cannot be readily

Received: 16 May 2020 Revised: 01 December 2020 Accepted: 01 December 2020

Accepted Manuscript online: 02 December 2020 Version of Record published: 05 January 2021






Figure 1. ApoD crystal structure and conformational changes upon progesterone binding

ApoD adopts a typical lipocalin fold with an eight-stranded  $\beta$ -barrel and an adjacent  $\alpha$ -helix. Three amino acids, Asn-45, Tyr-46 and Asn-78, show a conformational change upon progesterone binding.

employed to assess the influence of ligand binding to tetrameric apoD. SAXS, in contrast, is a solution based scattering technique that can determine the size and shape of biomolecules and allows structural modelling. In combination with crosslinking-mass spectrometry and the described model of glycosylated monomeric apoD [15], SAXS provided an opportunity to structurally model the apoD tetramer [8]. However, the impact that ligand binding may have on apoD oligomerisation and overall structure was not investigated, nor was the influence of oxidation of Met-93. Oxidation of Met-93 *in vitro* leads to apoD dimer formation and these dimers are also observed in the brain of Alzheimer's disease patients [16], a function unique to apoD in the lipocalin family. In the present study, we use SAXS to determine if ligand binding or oxidation affects oligomerisation or conformation of native human apoD.

# Materials and methods

The methods for apoD purification and SAXS analysis have been previously published in detail [8]. In the present study, we used the same experimental instrument conditions as described previously [8], in order to allow a direct comparison of the previously published data pertaining to the apo form of apoD with the data presented herein pertaining to the ligand-bound forms of apoD. The pertinent methodological information is provided below in brief.

# Sample preparation

ApoD was purified from human BCF using ion exchange chromatography and size exclusion chromatography (SEC) in SAXS-buffer (50 mM sodium phosphate, 150 mM NaCl, 3% (v/v) glycerol, pH 7.4) and SEC fractions were pooled to a concentration of 1.26 mg/ml (43  $\mu$ M). A Coomassie stained SDS-PAGE gel of the pooled fractions is shown in Supplementary Figure S1. For each ligand, 1 ml of apoD was diluted ten-fold with SAXS-buffer to a concentration of 4.3  $\mu$ M. Biliverdin ( $K_D$  unknown [17]), palmitic acid ( $K_D$  3.3  $\mu$ M [18]), progesterone ( $K_D$  1.7  $\mu$ M [19]) and palmitoyl sphingomyelin ( $K_D$  1.3  $\mu$ M [18]) were dissolved in dimethylformamide and added at 10× molar excess (30  $\mu$ l, final concentration 43  $\mu$ M) to apoD (10 ml, 4.3  $\mu$ M). The samples were inverted immediately after adding ligands to prevent ligand precipitation and incubated for 1 h at 22°C while gently inverting. Ligand occupancy was calculated according to (eqn 1):

$$Y = \frac{[ApoD \cdot L]}{[ApoD]_{total}} = \frac{([L]_{total} + [ApoD]_{tot} + K_d) - \sqrt{([L]_{tot} + [ApoD]_{tot} + K_d)^2 - 4 \cdot [ApoD]_{tot} \cdot [L]_{tot}}}{2 \cdot [ApoD]_{tot}}$$
(1)



Table 1 Sample and structural parameters for apoD in the ligand-bound and oxidised forms

	Biliverdin	Palmitic acid	Progesterone	Sphingomyelin	Oxidised (H <sub>2</sub> O <sub>2</sub> )
Loading concentration (mg/ml)	8.44	8.89	8.435	5.01	9.40
Guinier analysis					
$I(0) \text{ (cm}^{-1})$	$0.07701 \pm 0.00008$	$0.04668 \pm 0.00008$	$0.04536 \pm 0.00009$	$0.07839 \pm 0.0001$	$0.07375 \pm 0.00009$
$R_{g}$ (Å)	$33.4 \pm 0.1$	$33.4 \pm 0.2$	$33.4 \pm 0.3$	$33.3 \pm 0.2$	$33.4 \pm 0.1$
$q_{\min}$ (Å-1)	0.0099	0.0099	0.0111	0.0123	0.0099
gR <sub>g</sub> max	1.27	1.27	1.27	1.27	1.27
Coefficient of correlation, $R^2$	0.9997	0.9992	0.9987	0.9994	0.9996
P(r) analysis					
$I(0) \text{ (cm}^{-1})$	$0.07724 \pm 0.00008$	$0.04674 \pm 0.00007$	$0.04213 \pm 0.00007$	$0.07855 \pm 0.0001$	$0.07384 \pm 0.00007$
$R_{\rm g}$ (Å)	33.40 ± 0.05	$33.48 \pm 0.07$	$33.24 \pm 0.06$	$33.37 \pm 0.05$	33.41 ± 0.04
D <sub>max</sub> (Å)	105	106	100	99	103
q range (Å <sup>-1</sup> )	0.0099-0.239	0.0099-0.239	0.0099-0.239	0.0135-0.239	0.0099-0.239
$\chi^2$ (total estimate from GNOM)	1.08	1.02	1.14	0.97	1.21
Porod volume estimate (Å3)	168000	163000	161000	171000	164000
Molecular weight (kDa), calculated from I(0) and Abs <sub>280</sub>	86	87	96	103	92

For oxidation, 1 ml of apoD (43  $\mu$ M) was incubated with H<sub>2</sub>O<sub>2</sub> (final concentration 100 mM) overnight at 4°C. H<sub>2</sub>O<sub>2</sub> is known to oxidise free cysteines, lysine, histidines and glycines in addition to methionines [20].

Ligand-bound samples were buffer exchanged to remove unbound ligands and spin-concentrated using Amicon Ultra concentrators with an Ultracel-10 membrane (10 kDa molecular weight cut-off). Oxidised apoD was directly spin-concentrated and all samples were frozen at  $-80^{\circ}$ C. Final protein concentrations of all samples are listed in Table 1. All protein concentrations were measuring using a Pierce BCA assay (ThermoFisher) with bovine serum albumin serial dilution as standard curve according to the manufacturer's instructions.

# Small angle X-ray scattering data collection and analysis

SEC-SAXS data in coflow mode [21] were collected at the SAXS/WAXS beamline at the Australian Synchrotron, Clayton, Australia [22]. Samples were thawed on ice and spun for 10 min at 16 k  $\times$  g. A GE Superdex 200 5/150 column was equilibrated to SAXS-buffer and 100  $\mu$ l of ligand bound/oxidised apoD were applied to the column. SAXS parameters are listed in Supplementary Table S1. Primary data reduction was done in ScatterBrain (2.710), all other data analyses were performed using ATSAS package 2.8.2 [23]. For buffer subtraction, 30 frames before protein elution were selected, averaged and subtracted from the averaged data. Guinier and Porod distance distribution analyses were carried out using Primusqt. The molecular weights were calculated using I(0) [24], using contrasts and partial specific volumes calculated using MULCh [25]. All scattering data and parameters were deposited to SASBDB under the accession numbers SASDHJ5 (biliverdin), SASDHK5 (oxidised apoD), SASDHL5 (palmitic acid), SASDHM5 (progesterone) and SASDHN5 (sphingomyelin).

## **Graphs and image analysis**

Graphs were created using GraphPad Prism. Errors are based on counting statistics and error bars are not shown if they are smaller than symbol sizes.

## Results

To evaluate if ligand binding or oxidation influences apoD oligomeric state or causes structural rearrangement of apoD subunits, apoD was incubated with ligands (biliverdin, palmitic acid, progesterone or sphingomyelin) or oxidised using  $H_2O_2$ , and subjected to SEC-SAXS analysis. All SAXS parameters are presented in Supplementary Table S1 and  $R_g$  and scattering intensity I(0) across the SEC peak for all samples are shown in Figure 2A–E. No additional peaks other than the main peak at 255 s were observed (data not shown). To select appropriate areas for averaging, regions with constant  $R_g$  were identified. These areas were further assessed for inter-particle repulsion using Guinier and Porod analyses after averaging. Areas to be averaged were selected where no signs of aggregation and






Figure 2. Experimental SAXS data for ligand-bound and oxidised apoD tetramer

(A–E) Scattering intensity I(0) (dots) and radius of gyration  $R_{\rm g}$  (crosses) over apoD elution on an S200 5/150 SEC column for biliverdin-, palmitic acid-, progesterone-, sphingomyelin-bound and oxidised apoD. Areas with constant  $R_{\rm g}$  that showed no interparticle repulsion were selected for averaging (marked in red). (F–J) Total experimental scattering profile of ligand-bound or oxidised apoD. All scattering curves show the same overall shape and extent. Error bars in scattering profiles are based on counting statistics and error bars are not shown if they are smaller than symbol sizes.



Table 2 Comparison of SAXS parameters of ligand-free, ligand-bound and oxidised apoD

Sample	$R_{\mathrm{g}}$ (Å)	D <sub>max</sub> (Å)	Porod volume estimate (Å <sup>3</sup> )
<sup>1</sup> Apo-form	33.71 ± 0.07	110	169,000
Biliverdin	$33.40 \pm 0.05$	105	168,000
Palmitic acid	$33.48 \pm 0.07$	106	163,000
Progesterone	33.24 <u>+</u> 0.06	100	161,000
Sphingomyelin	33.37 ± 0.05	99	171,000
Oxidised (H <sub>2</sub> O <sub>2</sub> )	33.41 ± 0.04	103	164,000

<sup>&</sup>lt;sup>1</sup>Data derived from Kielkopf et al. [8] Parameters are derived from *P*(*r*) analysis.

inter-particle repulsion were present. Final averaged frames for further analysis are marked in red (Figure 2A–E), and total scattering profiles for these averaged frames are shown in Figure 2F–J.

Averaged and buffer-subtracted data for ligand-bound and oxidised apoD were evaluated in the Guinier region at small q values where no indication of aggregation or inter-particle repulsion was observed (Figure 3A–E). P(r) functions for each sample showed a bell shape that smoothly approached zero at  $D_{\text{max}}$  (Figure 3F–J). These curves correspond to a globular molecule and showed no signs of inter-particle repulsion.

Scattering profiles and P(r) curves for ligand-free apoD and ligand-bound and oxidised apoD were normalised to I(0) (as determined by P(r) analysis) and  $P(r)_{max}$ , respectively. Thereby, scattering profiles and P(r) curves of ligand-bound or oxidised apoD can be compared with ligand-free apoD more easily (Figure 4). Neither ligand binding nor oxidation using  $H_2O_2$  changed the scattering profile substantially (Figure 4A). A small difference can be noted in progesterone-bound apoD. The P(r) curves remained largely the same upon addition of ligand and oxidation (Figure 4B). Slight differences were only observed at high values of r, possibly indicating a reduction in  $D_{max}$  of ligand-bound and oxidised apoD compared with ligand-free apoD.

 $R_{\rm g}$  values calculated from P(r) analysis,  $D_{\rm max}$  and estimated Porod volumes of all studied samples are listed in Table 2. There were small changes in  $R_{\rm g}$ ,  $D_{\rm max}$  and Porod volume in ligand-bound or oxidised apoD compared with ligand-free apoD. Ligand-bound or oxidised apoD showed a decrease in  $R_{\rm g}$  of maximally 0.47 Å (progesterone-bound apoD).  $D_{\rm max}$  was decreased in all ligand-bound or oxidised samples of maximally 11 Š(sphingomyelin-bound apoD). The Porod volume varied from a decrease of 8000 ų (progesterone-bound apoD) to an increase of 2000 ų (sphingomyelin-bound apoD) compared with ligand-free apoD. Due to the inherent uncertainties of  $R_{\rm g}$ ,  $D_{\rm max}$  and Porod volume [26–31], none of these changes are considered significant.

## **Discussion**

SAXS as a solution-based scattering technique is a powerful method to determine size and shape of proteins and protein complexes. Our previously published SAXS experiments of ligand-free apoD revealed the nature of apoD as a tetrameric oligomer with an  $R_{\rm g}$  of  $\sim$ 33 Å and a globular structure [8]. The molecular weight of apoD calculated from the Porod analysis and I(0) was consistently determined at  $\sim$ 97 kDa, which is in good agreement with data derived from other biophysical analyses [8].

In the present study, when apoD was incubated with one of the apoD ligands biliverdin, palmitic acid, progesterone or sphingomyelin, or oxidised using  $H_2O_2$ , no significant changes in the scattering profile, Porod curve,  $R_{\rm g}$  or  $D_{\rm max}$  were detected (Figure 4 and Table 2). No additional peaks were observed in the size exclusion chromatogram (data not shown). These results indicate that ligand binding and oxidation do not lead to a change in apoD oligomeric state and do not cause substantial conformational changes or subunit rearrangements. Interestingly, HDX-MS showed a stabilisation of apoD dynamics upon progesterone binding but no major conformational changes [13], which is in agreement with the SAXS data presented here.

One potential confounding factor in the SAXS experiment could be an endogenous ligand co-purified with apoD from BCF. In the past, we characterised hydrophobic extracts from apoD using untargeted liquid chromatography-tandem mass spectrometry analysis. Progesterone or other potential apoD ligand such as free fatty acids or phospholipids were not identified (data not shown).

While the ligand occupancy of apoD during incubation with the ligands was calculated to be between 92% and 96%, the occupancy during the experiment may be lower due to the need to remove ligand and solvent before the SEC-SAXS experiment. HDX-MS experiments show that progesterone binding persists over a 2-h experiment at final concentrations of 10.7  $\mu$ M (apoD) and 3  $\mu$ M (progesterone) [13]. Notably, organic solvent was present during






Figure 3. Guinier and Porod analysis for ligand-bound and oxidised apoD

(A–E) Guinier plots of apoD bound to a ligand or oxidised apoD. Linear regression showed no up- or down-turn of the curve, indicating no aggregation or inter-particle repulsion. (F–J) P(r) functions of apoD bound to a ligand or oxidised apoD displayed a symmetric profile indicative of a mainly globular scattering molecule. All curves approach zero smoothly at high q, indicating the absence of inter-particle repulsion. Error bars in P(r) functions are based on counting statistics and error bars are not shown if they are smaller than symbol sizes.






Figure 4. Overlay of normalised scattering data and P(r) curves

(A) All scattering data for apoD in the apo-, ligand-bound and oxidised form were normalised to I(0), as calculated by Porod analysis, and overlaid. The shape of the scattering profiles was identical. (B) P(r) functions for apoD in the apo, ligand-bound and oxidised form were normalised to  $P(r)_{max}$  and overlaid. The shape of the Porod distribution was identical. However, there were slight variances at high radii. Error bars in scattering profiles are based on counting statistics and error bars are not shown if they are smaller than symbol sizes. Data for the apo-form of apoD are derived from Kielkopf et al. [8]

 $K_{\rm D}$  measurements for most apoD ligands, thereby influencing the off-rate and the  $K_{\rm D}$  [32–34]. In the here presented SAXS experiments, the organic solvent was removed in the process, thereby reducing the solubility of the hydrophobic ligand in the aqueous surrounding and limiting the ligand off rate. Including free ligand in the running buffer is not practical for hydrophobic ligands as the amount of solvent required could influence the structural integrity of the protein [35–37].

SAXS studies of the lipocalins lipocalin-type prostaglandin D synthase (PGDS), bovine β-lactoglobulin A and retinol-binding protein have been performed upon binding of retinoic acid. In addition, SAXS was performed on PGDS upon binding of bilirubin and biliverdin [38]. SAXS showed an  $R_g$  reduction in PGDS of up to 2.1 Å upon ligand binding, but no changes were observed in β-lactoglobulin and retinol-binding protein. Further SAXS experiments combined with NMR using PGDS identified tightening in loop and helix regions of PGDS when bound to biliverdin [39]. Taking the inherent uncertainty of  $R_g$  and  $D_{max}$  into account, our study of apoD showed no difference in  $R_g$  and  $D_{\text{max}}$ , similarly to  $\beta$ -lactoglobulin and retinol-binding protein. Although the exact ligand occupancy of apoD was not quantitatively assessed in the present work, previous studies indicate that hydrophobic ligands such as those used by us herein are much less soluble in aqueous environment, consistent with their stable binding within the lipophilic binding pocket of apoD; a feature that is common among other members of the lipocalin family [38,39]. Similar to apoD, X-ray crystallography of PGDS showed conformational changes in single amino acids and in a single loop when PGDS was bound to a substrate analogue [40] or fatty acids (pdb accession number 3O22). These data underline the importance of SAXS as a sensitive solution-based structural technique in characterising interactions of proteins with hydrophobic ligands. Furthermore, these examples suggest that the structural response of a lipocalin to ligand binding depends on the specific lipocalin and ligand, as is the case for other proteins [41]. This may reflect the fact that many lipocalins bind a spectrum of ligands, potentially resulting in a variety of scenarios upon ligand binding.

In conclusion, ligand binding or oxidation did not induce significant changes to the native oligomeric status of apoD, nor did these parameters induce substantial conformational change or subunit rearrangements as determined by SAXS analysis. The present study highlights the highly stable structure of the native apoD tetramer under various physiologically relevant experimental conditions.

## **Data Availability**

All scattering data and parameters were deposited to SASBDB under the accession numbers SASDHJ5 (biliverdin), SASDHK5 (oxidised apoD), SASDHL5 (palmitic acid), SASDHM5 (progesterone) and SASDHN5 (sphingomyelin). All other data required for replicating this study are given in the manuscript.

#### Competing Interests

The authors declare that there are no competing interests associated with the manuscript.



## **Funding**

Travel support for the SAXS experiments was granted by the Australian Synchrotron. B.G. was supported by a fellowship from the NHMRC (1109831)

#### **Author Contribution**

C.S.K. and S.H.J.B. performed the experiments, and C.S.K., A.E.W. and S.H.J.B. performed data analysis. B.G. and S.H.J.B. designed the experiment. C.S.K., A.E.W., B.G. and S.H.J.B. wrote the manuscript.

### **Acknowledgements**

The SAXS experiments were undertaken on the SAXS/WAXS beamline at the Australian Synchrotron, part of ANSTO. Thanks to Dr Timothy Ryan from the SAXS/WAXS beamline at the Australian Synchrotron, for help and advice with the SAXS experiments and data analysis.

### **Abbreviations**

apoD, apolipoprotein-D; BCF, breast cyst fluid; HDX-MS, hydrogen-deuterium exchange coupled with mass spectrometry; PGDS, prostaglandin D synthase; SAXS, small-angle X-ray scattering; SEC, size-exclusion chromatography.

#### References

- 1 Eichinger, A. et al. (2007) Structural insight into the dual ligand specificity and mode of high density lipoprotein association of apolipoprotein D. *J. Biol. Chem.* **282**, 31068–31075, https://doi.org/10.1074/jbc.M703552200
- 2 McConathy, W.J. and Alaupovic, P. (1973) Isolation and partial characterization of apolipoprotein D: a new protein moiety of the human plasma lipoprotein system. FEBS Lett. 37, 178–182, https://doi.org/10.1016/0014-5793(73)80453-3
- 3 Akerstrom, B., Flower, D.R. and Salier, J.P. (2000) Lipocalins: unity in diversity. *Biochim. Biophys. Acta* 1482, 1–8, https://doi.org/10.1016/S0167-4838(00)00137-0
- 4 Blanco-Vaca, F. et al. (1992) Characterization of disulfide-linked heterodimers containing apolipoprotein D in human plasma lipoproteins. J. Lipid Res. 33. 1785–1796
- 5 Schindler, P.a. et al. (1995) Site-specific detection and structural characterization of the glycosylation of human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D using HPLC/electrospray mass spectrometry and sequential glycosidase digestion. *Protein Sci.* 4, 791–803, https://doi.org/10.1002/pro.5560040419
- 6 Bhatia, S. et al. (2012) Selective reduction of hydroperoxyeicosatetraenoic acids to their hydroxy derivatives by apolipoprotein D: implications for lipid antioxidant activity and Alzheimer's disease. *Biochem. J.* 442, 713–721, https://doi.org/10.1042/BJ20111166
- 7 Li, H. et al. (2015) Apolipoprotein D modulates amyloid pathology in APP/PS1 Alzheimer's disease mice. Neurobiol. Aging 36, 1820–1833, https://doi.org/10.1016/j.neurobiolaging.2015.02.010
- 8 Kielkopf, C.S. et al. (2018) Identification of a novel tetrameric structure for human apolipoprotein-D. J. Struct. Biol. 203, 205–218, https://doi.org/10.1016/j.jsb.2018.05.012
- 9 Mans, B.J. and Neitz, A.W. (2004) Molecular crowding as a mechanism for tick secretory granule biogenesis. *Insect. Biochem. Mol. Biol.* 34, 1187–1193, https://doi.org/10.1016/j.ibmb.2004.07.007
- 10 Qin, B.Y. et al. (1998) Structural basis of the Tanford transition of bovine beta-lactoglobulin. *Biochemistry* **37**, 14014–14023, https://doi.org/10.1021/bi981016t
- 11 Gutierrez-Magdaleno, G. et al. (2013) Ligand binding and self-association cooperativity of beta-lactoglobulin. *J. Mol. Recognit.* **26**, 67–75, https://doi.org/10.1002/jmr.2249
- 12 Gamiz-Hernandez, A.P. et al. (2015) Protein-Induced Color Shift of Carotenoids in beta-Crustacyanin. *Angew. Chem. Int. Ed. Engl.* **54**, 11564–11566, https://doi.org/10.1002/anie.201501609
- 13 Kielkopf, C.S. et al. (2019) HDX-MS reveals orthosteric and allosteric changes in apolipoprotein-D structural dynamics upon binding of progesterone. *Protein Sci.* 28, 365–374, https://doi.org/10.1002/pro.3534
- 14 Nasreen, A. et al. (2006) Solubility engineering and crystallization of human apolipoprotein D. Protein Sci. 15, 190–199, https://doi.org/10.1110/ps.051775606
- 15 Oakley, A.J. et al. (2012) Molecular dynamics analysis of apolipoprotein-D-lipid hydroperoxide interactions: mechanism for selective oxidation of Met-93. *PLoS ONE* **7**, e34057, https://doi.org/10.1371/journal.pone.0034057
- 16 Bhatia, S. et al. (2013) Increased apolipoprotein D dimer formation in alzheimer's disease hippocampus is associated with lipid conjugated diene levels. *J. Alzheimers Dis.* **35**, 475–486, https://doi.org/10.3233/JAD-122278
- 17 Peitsch, M.C. and Boguski, M.S. (1990) Is apolipoprotein D a mammalian bilin-binding protein? New Biol. 2, 197–206
- 18 Ruiz, M. et al. (2013) Lipid-binding properties of human ApoD and Lazarillo-related lipocalins: Functional implications for cell differentiation. *FEBS J.* **280**, 3928–3943, https://doi.org/10.1111/febs.12394
- 19 Vogt, M. and Skerra, A. (2001) Bacterially produced apolipoprotein D binds progesterone and arachidonic acid, but not bilirubin or E-3M2H. *J. Mol. Recognit.* **14**, 79–86, https://doi.org/10.1002/1099-1352(200101/02)14:1%3c79::AID-JMR521%3e3.0.C0;2-4



- 20 Finnegan, M. et al. (2010) Mode of action of hydrogen peroxide and other oxidizing agents: differences between liquid and gas forms. *J. Antimicrob. Chemother.* **65**, 2108–2115, https://doi.org/10.1093/jac/dkq308
- 21 Kirby, N. et al. (2016) Improved radiation dose efficiency in solution SAXS using a sheath flow sample environment. *Acta Crystallogr. D. Struct. Biol.* **72**, 1254–1266, https://doi.org/10.1107/S2059798316017174
- 22 Kirby, N.M. et al. (2013) A low-background-intensity focusing small-angle X-ray scattering undulator beamline. J. Appl. Crystallogr. 46, 1670–1680, https://doi.org/10.1107/S002188981302774X
- 23 Franke, D. et al. (2017) ATSAS 2.8: a comprehensive data analysis suite for small-angle scattering from macromolecular solutions. *J. Appl. Crystallogr.* **50**, 1212–1225, https://doi.org/10.1107/S1600576717007786
- 24 Petoukhov, M.V. et al. (2012) New developments in the ATSAS program package for small-angle scattering data analysis. *J. Appl. Crystallogr.* **45**, 342–350, https://doi.org/10.1107/S0021889812007662
- 25 Whitten, A.E., Cai, S. and Trewhella, J. (2008) MULCh: modules for the analysis of small-angle neutron contrast variation data from biomolecular assemblies. *J. Appl. Crystallogr.* **41**, 222–226, https://doi.org/10.1107/S0021889807055136
- 26 Jacques, D.A. et al. (2012) Publication guidelines for structural modelling of small-angle scattering data from biomolecules in solution. *Acta Crystallogr. D. Biol. Crystallogr.* **68**, 620–626, https://doi.org/10.1107/S0907444912012073
- 27 Trewhella, J. et al. (2017) 2017 publication guidelines for structural modelling of small-angle scattering data from biomolecules in solution: an update. Acta Crystallogr. D. Struct. Biol. 73, 710–728, https://doi.org/10.1107/S2059798317011597
- 28 Sedlak, S.M., Bruetzel, L.K. and Lipfert, J. (2017) Quantitative evaluation of statistical errors in small-angle X-ray scattering measurements. *J. Appl. Crystallogr.* **50**, 621–630, https://doi.org/10.1107/S1600576717003077
- 29 Grant, T.D. et al. (2015) The accurate assessment of small-angle X-ray scattering data. Acta Crystallogr. D. Biol. Crystallogr. 71, 45–56, https://doi.org/10.1107/S1399004714010876
- 30 Petoukhov, M.V. et al. (2007) ATSAS 2.1-towards automated and web-supported small-angle scattering data analysis. *Appl. Crystallogr.* **40**, s223–s228, https://doi.org/10.1107/S0021889807002853
- 31 Svergun, D. (1992) Determination of the regularization parameter in indirect-transform methods using perceptual criteria. *J. Appl. Crystallogr.* **25**, 495–503, https://doi.org/10.1107/S0021889892001663
- 32 Breustedt, D.A., Schönfeld, D.L. and Skerra, A. (2006) Comparative ligand-binding analysis of ten human lipocalins. *Biochim. Biophys. Acta* **1764**, 161–173, https://doi.org/10.1016/j.bbapap.2005.12.006
- 33 Papaneophytou, C.P. et al. (2014) Quantification of the effects of ionic strength, viscosity, and hydrophobicity on protein-ligand binding affinity. *ACS Med. Chem. Lett.* **5**, 931–936, https://doi.org/10.1021/ml500204e
- 34 Cubrilovic, D. and Zenobi, R. (2013) Influence of dimehylsulfoxide on protein-ligand binding affinities. *Anal. Chem.* **85**, 2724–2730, https://doi.org/10.1021/ac303197p
- 35 Jackson, M. and Mantsch, H.H. (1991) Beware of proteins in DMSO. Biochim. Biophys. Acta 1078, 231–235, https://doi.org/10.1016/0167-4838(91)90563-F
- 36 Tjernberg, A. et al. (2006) DMSO-related effects in protein characterization. J. Biomol. Screen. 11, 131–137, https://doi.org/10.1177/1087057105284218
- 37 Krainer, G. et al. (2012) Quantifying high-affinity binding of hydrophobic ligands by isothermal titration calorimetry. *Anal. Chem.* **84**, 10715–10722, https://doi.org/10.1021/ac3025575
- 38 Inoue, K. et al. (2009) Compact packing of lipocalin-type prostaglandin D synthase induced by binding of lipophilic ligands. *J. Biochem.* **145**, 169–175, https://doi.org/10.1093/jb/mvn154
- 39 Miyamoto, Y. et al. (2010) Structural analysis of lipocalin-type prostaglandin D synthase complexed with biliverdin by small-angle X-ray scattering and multi-dimensional NMR. *J. Struct. Biol.* **169**, 209–218, https://doi.org/10.1016/j.jsb.2009.10.005
- 40 Lim, S.M. et al. (2013) Structural and dynamic insights into substrate binding and catalysis of human lipocalin prostaglandin D synthase. *J. Lipid Res.* **54**, 1630–1643, https://doi.org/10.1194/jlr.M035410
- 41 Gunasekaran, K. and Nussinov, R. (2007) How different are structurally flexible and rigid binding sites? Sequence and structural features discriminating proteins that do and do not undergo conformational change upon ligand binding. *J. Mol. Biol.* **365**, 257–273, https://doi.org/10.1016/j.jmb.2006.09.062